SCHEDULE 13G/A: Dr. Arie Belldegrun and Affiliated Entities Update Significant Stake in Allogene Therapeutics
Beneficial Ownership Disclosure
Dr. Arie Belldegrun and associated entities have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 12,543,444 shares, or 5.7%, of Allogene Therapeutics, Inc. common stock as of March 31, 2025.
Summary
- Dr. Arie Belldegrun, M.D., reported beneficial ownership of 12,543,444 shares of Allogene Therapeutics, Inc. common stock, representing 5.7% of the class.
- This aggregate amount for Dr. Belldegrun includes 3,180,554 shares of common stock issuable within 60 days of March 31, 2025, upon the exercise of stock options.
- Dr. Belldegrun's reported ownership also includes shares held by entities he manages or is a Senior Managing Director of, such as Bellco Legacy IV LLC, Bellco Legacy LLC, Vida Ventures LLC, Vida Ventures III, L.P., and Vida Ventures III-A, L.P.
- Bellco Legacy LLC reported beneficial ownership of 539,867 shares, or 0.2% of the class.
- Bellco Legacy IV LLC reported beneficial ownership of 4,710,120 shares, or 2.1% of the class.
- Vida Ventures LLC reported beneficial ownership of 1,798,163 shares, or 0.8% of the class.
- Vida Ventures III, L.P. reported beneficial ownership of 1,720,172 shares, or 0.8% of the class.
- Vida Ventures III-A, L.P. reported beneficial ownership of 3,965 shares, or 0.0% of the class.
- The percentages of ownership are calculated based on 217,264,738 shares of common stock outstanding as of March 7, 2025, as reported in Allogene Therapeutics' Quarterly Report on Form 10-K filed on March 13, 2025.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Dr. Arie Belldegrun, M.D., is a manager of Bellco Legacy LLC and Bellco Legacy IV LLC (along with Rebecka Belldegrun), which beneficially own shares of Allogene Therapeutics.
- Dr. Arie Belldegrun is a Senior Managing Director of VV Manager LLC, which is the manager of Vida Ventures LLC, a beneficial owner of Allogene Therapeutics shares.
- Dr. Arie Belldegrun is a Senior Managing Director of Vida Ventures GP III, LLC, which is the manager of Vida Ventures III, L.P. and Vida Ventures III-A, L.P., both beneficial owners of Allogene Therapeutics shares.
- Dr. Belldegrun disclaims beneficial ownership of the shares held by Vida Ventures LLC, Vida Ventures III, L.P., and Vida Ventures III-A, L.P., except to the extent of any pecuniary interest therein and for the purpose of determining his obligations under Section 13(d) of the Exchange Act.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant ownership stakes by Dr. Arie Belldegrun and affiliated investment entities, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 03/07/2025 | Date as of which 217,264,738 shares of common stock were outstanding, as reported in the Issuer's Quarterly Report on Form 10-K. |
| 03/13/2025 | Date Issuer's Quarterly Report on Form 10-K was filed. |
| 03/31/2025 | Date of event which requires filing of this Schedule 13G statement. |
| 05/09/2025 | Date of filing of this Schedule 13G amendment. |
Keywords
Allogene Therapeutics, Arie Belldegrun, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Healthcare Investment, Vida Ventures, Bellco Legacy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.